Low Cost and Effective Drug to Treat Central Retinal Vein Occlusion (CRVO)

Retinal vein occlusion (RVO) is the second most common eye disease after diabetic retinopathy. Around 16 million people are affected with the disease every year in the world. Bevacizumab (Avastin) drug found to be as effective as Aflibercept (Eylea) drug for treating central retinal vein occlusion in the eye, finds a new study funded by the National Eye Institute (NEI).
Email bookmark
Font : A-A+

Related Links